(Total Views: 450)
Posted On: 01/21/2021 11:24:14 AM
Post# of 154479
Any links to that? I can find no evidence that Dr. Patterson ever said that.
With receptor occupancy I think the problem is with the newness of Dr. Patterson's test not how well it performs. In addition receptor occupancy tests were not part of the protocol for the trial.
That the FDA would be asking for occupancy tests after the fact for a protocol that they initially approved just goes to show the FDA is not trustworthy. But there is new leadership at the FDA and approval for COVID-19 will put a glaring spotlight on leronlimab and how the FDA has dealt with it in the past.
With receptor occupancy I think the problem is with the newness of Dr. Patterson's test not how well it performs. In addition receptor occupancy tests were not part of the protocol for the trial.
That the FDA would be asking for occupancy tests after the fact for a protocol that they initially approved just goes to show the FDA is not trustworthy. But there is new leadership at the FDA and approval for COVID-19 will put a glaring spotlight on leronlimab and how the FDA has dealt with it in the past.
(5)
(0)
